Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report

Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yuki Katsumata, Yoshihide Kawasaki, Kayu Tanaka, Daisuke Nakayama, Hiromichi Katayama, Shuichi Shimada, Yohei Satake, Takuma Sato, Naoki Kawamorita, Shinichi Yamashita, Testuya Sato, Kosuke Shoji, Koji Mitsuzuka, Akihiro Ito
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
Acceso en línea:https://doaj.org/article/f836686a18da49219a96dc9f58f4a191
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f836686a18da49219a96dc9f58f4a191
record_format dspace
spelling oai:doaj.org-article:f836686a18da49219a96dc9f58f4a1912021-11-18T11:08:46ZCombination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report1662-657510.1159/000519855https://doaj.org/article/f836686a18da49219a96dc9f58f4a1912021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/519855https://doaj.org/toc/1662-6575Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiotherapy for metastatic lesions of the ipsilateral kidney was performed 9 years after right laparoscopic radical nephrectomy. Soon after, the patient started to receive hemodialysis due to end-stage renal disease. Further stereoscopic radiotherapy was needed for metastasis of the ipsilateral kidney and lung. Fifteen years after diagnosis, systemic therapy was necessary to control new metastases, such as in the right scapular bone. We selected pembrolizumab plus axitinib combination therapy as the first-line systemic therapy for any risk as defined by the International Metastatic RCC Database Consortium. Although we needed to pay attention to the adverse events unique to hemodialysis, he underwent this combination therapy without any difficulty for 6 months. Here, we report the practice of combination therapy in patients on hemodialysis in light of the literature.Yuki KatsumataYoshihide KawasakiKayu TanakaDaisuke NakayamaHiromichi KatayamaShuichi ShimadaYohei SatakeTakuma SatoNaoki KawamoritaShinichi YamashitaTestuya SatoKosuke ShojiKoji MitsuzukaAkihiro ItoKarger Publishersarticleaxitinibhemodialysispembrolizumabrenal cell carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1522-1529 (2021)
institution DOAJ
collection DOAJ
language EN
topic axitinib
hemodialysis
pembrolizumab
renal cell carcinoma
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle axitinib
hemodialysis
pembrolizumab
renal cell carcinoma
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Yuki Katsumata
Yoshihide Kawasaki
Kayu Tanaka
Daisuke Nakayama
Hiromichi Katayama
Shuichi Shimada
Yohei Satake
Takuma Sato
Naoki Kawamorita
Shinichi Yamashita
Testuya Sato
Kosuke Shoji
Koji Mitsuzuka
Akihiro Ito
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
description Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiotherapy for metastatic lesions of the ipsilateral kidney was performed 9 years after right laparoscopic radical nephrectomy. Soon after, the patient started to receive hemodialysis due to end-stage renal disease. Further stereoscopic radiotherapy was needed for metastasis of the ipsilateral kidney and lung. Fifteen years after diagnosis, systemic therapy was necessary to control new metastases, such as in the right scapular bone. We selected pembrolizumab plus axitinib combination therapy as the first-line systemic therapy for any risk as defined by the International Metastatic RCC Database Consortium. Although we needed to pay attention to the adverse events unique to hemodialysis, he underwent this combination therapy without any difficulty for 6 months. Here, we report the practice of combination therapy in patients on hemodialysis in light of the literature.
format article
author Yuki Katsumata
Yoshihide Kawasaki
Kayu Tanaka
Daisuke Nakayama
Hiromichi Katayama
Shuichi Shimada
Yohei Satake
Takuma Sato
Naoki Kawamorita
Shinichi Yamashita
Testuya Sato
Kosuke Shoji
Koji Mitsuzuka
Akihiro Ito
author_facet Yuki Katsumata
Yoshihide Kawasaki
Kayu Tanaka
Daisuke Nakayama
Hiromichi Katayama
Shuichi Shimada
Yohei Satake
Takuma Sato
Naoki Kawamorita
Shinichi Yamashita
Testuya Sato
Kosuke Shoji
Koji Mitsuzuka
Akihiro Ito
author_sort Yuki Katsumata
title Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
title_short Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
title_full Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
title_fullStr Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
title_full_unstemmed Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
title_sort combination therapy of pembrolizumab plus axitinib for a patient on hemodialysis with metastatic renal cell carcinoma: a case report
publisher Karger Publishers
publishDate 2021
url https://doaj.org/article/f836686a18da49219a96dc9f58f4a191
work_keys_str_mv AT yukikatsumata combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT yoshihidekawasaki combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT kayutanaka combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT daisukenakayama combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT hiromichikatayama combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT shuichishimada combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT yoheisatake combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT takumasato combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT naokikawamorita combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT shinichiyamashita combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT testuyasato combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT kosukeshoji combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT kojimitsuzuka combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
AT akihiroito combinationtherapyofpembrolizumabplusaxitinibforapatientonhemodialysiswithmetastaticrenalcellcarcinomaacasereport
_version_ 1718420881703698432